[The influence of Ara-C on anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells.].
OBJECTIVE
To investigate the role of Ara-C in regulating anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells.


METHODS
The diabody of anti-CD3/anti-Pgp was purified by E-tag affinity chromatography. K562 and K562/A02 cells were treated with Ara-C. The expressions of B7-1 and B7-2 on K562 and K562/AO2 cells were detected by FACS. The cytotoxicity of T-lymphocytes combined with anti-CD3/anU-Pgp plus Ara-C was analyzed by CytoTox 96 nonradioactive method.


RESULTS
The expressions of B7-1 and B7-2 on K562 and K562/A02 cells treated by Ara-C was significantly higher than those untreated. The effect/target ratio was from 0.39:1 to 25:1, and the killing rate of activated T cells to anti-drug-resistant leukemia cells was from (16.44 +/- 1.20)% to (60.49 +/- 2.90)%. The killing rates were increased gradually, with both the effect/target ratio and the antibody concentration increasing (P < 0.05).


CONCLUSIONS
Ara-C may be an important adjuvant for improving anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells.
Yang
Ming
M
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
Fan
Dong-Mei
DM
Gao
Ying-Dai
YD
Zhou
Yuan
Y
Ji
Qing
Q
Shao
Xiao-Feng
XF
Wang
Jin-Hong
JH
Xu
Yuan-Fu
YF
Xiong
Dong-Sheng
DS
Yang
Chun-Zheng
CZ
D003561:Cytarabine; D006801:Humans; D020014:K562 Cells; D007938:Leukemia / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D003561:Cytarabine